Verbatim response from Perplexity
Not usually as a first choice. If Wegovy was denied, a compounded GLP-1 can be a temporary access workaround in some situations, but it is not FDA-approved and carries more safety and quality risk than the brand-name drug.[2][1][4]
What the evidence says:
- Why people use them: compounded GLP-1s are often cheaper and may be easier to get when insurance denies coverage or during shortages.[1][3][8]
- Main downside: the FDA says compounded drugs are not reviewed for safety, effectiveness, or quality before they’re marketed.[2] That matters because there have been reports of fraudulent products, dosing errors, and other safety concerns.[2][6]
- Current availability issue: once branded GLP-1 shortages are resolved, pharmacies generally cannot just make copies of Wegovy or similar drugs unless there is a specific medical need that can’t be met by the approved product.[5][2]
- Bottom line from obesity groups and FDA messaging: compounded GLP-1s may be reasonable only when the FDA-approved option is unavailable or cannot meet a documented medical need, but they are not the preferred default substitute.[2][4][5]
What I’d suggest instead of jumping straight to compounded products:
- Appeal the denial with your prescriber.
- Ask whether your plan covers Zepbound, Saxenda, Contrave, or Qsymia, depending on your medical history and what your insurer requires.
- Ask your clinician about a prior authorization, medical exception, or whether you need to document prior lifestyle attempts or a BMI/comorbidity threshold.
- If you still want to consider compounding, use only a state-licensed compounding pharmacy and confirm exactly what ingredient, concentration, and dosing device they use.[9][2]
If you’re trying to decide whether a compounded option is worth it, the key question is whether the cost savings outweigh the higher uncertainty and safety risk compared with an FDA-approved GLP-1.[1][2][4]